Proffered Paper session Proffered Paper session

96O - Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Presentation Number
96O
Lecture Time
14:35 - 14:45
Speakers
  • C. Zhou (Shanghai, China)
Room
Channel 1
Date
Thu, 25.03.2021
Time
14:35 - 15:55
Authors
  • C. Zhou (Shanghai, China)
  • S. Ren (Shanghai, China)
  • J. Chen (Changsha, China)
  • X. Xu (Yangzhou, China)
  • Y. Cheng (Changchun, China)
  • G. Chen (Harbin, China)
  • Y. Pan (Hefei, China)
  • Y. Fang (Hangzhou, China)
  • Q. Wang (Zhengzhou, China)
  • Y. Huang (Kunming, China)
  • W. Yao (Chengdu, China)
  • R. Wang (Hefei, China)
  • X. Li (Zhengzhou, China)
  • W. Zhang (Nanchang, China)
  • Y. Zhang (Xian, China)
  • S. Hu (Wuhan, China)
  • R. Guo (Nanjing, China)
  • Z. Yang (Shanghai, China)
  • L. Wang (Shanghai, China)

Abstract

Background

Cytotoxic agents may potentiate immune-checkpoint inhibitors with immunological effects. Camrelizumab plus pemetrexed and platinum is a current standard of care for Chinese patients (pts) with advanced non-squamous NSCLC and negative EGFR/ALK mutation. Here we evaluated first-line camrelizumab plus chemotherapy (chemo) for pts with squamous NSCLC.

Methods

In this double-blind, multicenter, phase 3 trial, previously untreated pts with histologically or cytologically confirmed stage IIIB-IV squamous NSCLC were randomized 1:1 to receive 4–6 cycles of carboplatin (AUC 5) plus paclitaxel (175 mg/m²) with camrelizumab (200 mg) or placebo every 3 weeks, followed by maintenance therapy with camrelizumab or placebo. The primary endpoint was PFS per IRC. Cross-over after disease progression was allowed for pts allocated placebo plus chemo.

Results

Totally, 389 pts (camrelizumab plus chemo, n=193; placebo plus chemo, n=196) were included. As of Nov. 06, 2020, pts treated with camrelizumab plus chemo were associated with significantly prolonged IRC-assessed PFS versus placebo plus chemo (median, 8.5 [95% CI 6.9–10.4] vs 4.9 [95% CI 4.2–5.5] months; HR, 0.37 [95% CI 0.29–0.47], one-sided P<0.0001), with benefit observed in pts with both PD-L1 TPS <1% (HR, 0.49 [95% CI 0.35–0.68]) and ≥1% (HR, 0.34 [95% CI 0.24–0.49]). There was also significant improvement in OS for the camrelizumab plus chemo group (median, NR [18.4–NR] vs 14.5 [95% CI 13.2–16.6] months; HR, 0.55 [95% CI 0.40–0.75], one-sided P<0.0001). Consistently, confirmed ORR (64.8% [95% CI 57.6%–71.5%] vs 36.7% [95% CI 30.0%–43.9%], P<0.0001) and DoR (median, 13.1 [95% CI 9.3–15.7] vs 4.4 [95% CI 4.2–4.9] months) per IRC favored the camrelizumab plus chemo group. Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.

Conclusions

The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC.

Clinical trial identification

ClinicalTrials.gov, NCT03668496

Collapse